Incepta Pharmaceuticals Ltd. is a leading pharmaceutical company in Bangladesh established in the year 1999.
The company has a very big manufacturing facility located at Savar and Dhamrai, 35 and 53 kilometer away respectively from the center of the capital city Dhaka. The company produces various types of dosage forms which include tablets, capsules, oral liquids, ampoules, dry powder vials, powder for suspension, nasal sprays, eye drops, creams, ointments, lotions, gels, prefilled syringes, liquid filled hard gelatin capsules, lyophilized injections, human vaccine etc. Since its inception, Incepta has been launching new and innovative products in order to fulfill unmet demand of the medical community. The focus has been to bring more new technologically advanced molecules to this country.
The company specializes in value added high technology dosage forms like sustained release tablets, quick mouth dissolving tablets, effervescent tablets, barrier coated delayed release tablets, prefilled syringe products, Insulin and Insulin analogue and biological products, among others . It has established a modern research and development laboratory for the development of new, advanced dosage forms for various drugs and devices like poorly soluble drugs, dry powder inhalers, coated pellets, modified release products, taste masked preparation etc.
Incepta has a very competent sales team, which promotes the specialties throughout the country. The company virtually covers every single corner of the rural as well as urban area of Bangladesh. It has its own large distribution network having 21 depots all over the country. The company has a clear vision to become a leading research based dosage form manufacturing company with global presence within a short period of time. With this view in mind the company started to expand its business in overseas markets. Currently Incepta exports to 60 different countries around the world. With hundreds of brands registered in different countries, and many more in the pipeline, Incepta is gradually expanding its global footprint across all the continents.
Company's state-of-the-Art R&D lab employs sophisticated and advanced technology to bring newer products through research hitherto unknown in this country.
Such activities will not only benefit the company but also the total pharmaceutical sector of the country. Within very short possible time the company is going to to embark into the production of Active Pharmaceutical Ingredient (API). Plans are underway to get into reverse engineering and analogue research in order to produce new API.
Incepta Vaccines Limited, a sister concern of Incepta Pharmaceuticals, has already established a State-of-the-Art Human Vaccine production facility. Incepta Vaccines Ltd has already launched human vaccines in the Bangladesh market in June 2011. Incepta emerges as the first Bangladeshi company to acquire the technology to produce Human Vaccine. The larger production capacity will allow the company to supply its vaccines globally.
The company is continuously expanding its activities beyond the geographical boundary of Bangladesh. The company is open to collaborate with interested and relevant parties in various countries Incepta will continue to strive to provide high quality medicine at affordable prices to the people here in Bangladesh and other parts of the globe.
We market our products in 60 countries of the world through our distribution partners.
We manufacture more than 783 products from 32 therapeutic classes.